Digest Network Come funziona
Network
/
Società
Im
Non verificato

Imbrium Therapeutics L.P.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

7 comunicati stampa

Guarda tutti i comunicati
09/09/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Industria
Results From Sunobinop Phase 1B Study in Patients With Interstitial Cystitis/Bladder Pain Syndrome Announced
Fonte
Imbrium Therapeutics L.P.
Emittente
Business Wire
1.00
0
16/06/2025
Biotecnologia
Salute
Oncologia
Medicina - Varie
Eventi
Imbrium Therapeutics to Showcase Pipeline Assets Open for Partnership at the BIO International Convention 2025
Fonte
Imbrium Therapeutics L.P.
Emittente
Business Wire
1.00
0
11/03/2025
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Potential Treatment for Interstitial Cystitis/Bladder Pain Syndrome
Fonte
Imbrium Therapeutics L.P.
Emittente
Business Wire
1.00
0
07/01/2025
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Imbrium Therapeutics Announces Results of a Sunobinop Phase 1b Study in Patients With Overactive Bladder Syndrome
Fonte
Imbrium Therapeutics L.P.
Emittente
Business Wire
1.00
0
18/11/2024
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Imbrium Therapeutics Completes First Patient Dosed in Phase 2 Study to Evaluate Sunobinop for the Potential Treatment of Alcohol Use Disorder
Fonte
Imbrium Therapeutics L.P.
Emittente
Business Wire
1.00
0
05/08/2024
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Imbrium Therapeutics Submits Investigational New Drug Application to Evaluate Sunobinop for the Potential Treatment of Alcohol Use Disorder
Fonte
Imbrium Therapeutics L.P.
Emittente
Business Wire
1.00
0
09/07/2024
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Potential Treatment for Overactive Bladder Syndrome
Fonte
Imbrium Therapeutics L.P.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0